We are holding steady to our fair value estimate and wide moat rating for Pfizer PFE following first-quarter results that largely matched our expectations. The company is tracking well to meet its ...

Pfizer (PFE) remains in focus for income oriented investors, with recent returns ranging from a 2.1% decline over the past week to a 10.7% total return over the past year. See our latest analysis for ...

Pfizer PFE reported fourth-quarter earnings ahead of our expectations, largely due to lower-than-expected research and development spending. However, we don’t expect this will continue, so there is no ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Pfizer (NYSE:PFE) and Astellas reported Phase 3 data showing PADCEV plus Keytruda delivered significant clinical benefits in muscle-invasive bladder cancer. The combination was associated with ...

Activist investor Starboard Value has amassed a $1 billion stake in Pfizer, according to a report, with a turnaround in its sights. The pharmaceutical company has been struggling postpandemic to ...

Pfizer says it is standing behind its dividend, which makes the stock's 6.4% yield quite attractive.